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S288 Poster Session IIwith markedly reduced risk for GVHD in lethally irradiated mice
(Ophir et al Blood 2010). We now show that these Tcm can also en-
hance engraftment following sublethal TBI (5.5Gy). Thus, while all
13 BALB/c recipients of 107 Nude-B6 BM cells rejected the graft by
day 30, 6/7mice receiving also 5x106 (B6xBALB/c)F1Tcm exhibited
near full chimerism (81611%,. 6 months follow up). Importantly,
chimerism was associated with successful engraftment of donor skin
(. 3 months follow up) in 4/5 chimeras, while 3rd-party unrelated
skin was promptly rejected. When allogeneic B6 Tcm were used,
9/9 mice displayed full donor chimerism and 5/7 maintained donor
skin for over 3 months, without any GVHD symptoms (weight and
overall appearance were the same as that of control mice). Consider-
ing that RIC may be associated with increased relapse rate, it was of
interest to evaluate the GVL reactivity of Tcm. We previously
showed that anti 3rd-party human CTLs eliminate B-CLL and other
lymphoma types by unique TCR independent mechanism. This kill-
ing initiates with ICAM1-LFA1 adhesion, followed by slow apopto-
sis induced by interaction of CD8 on the CTL with MHC-I on the
tumor cell. Initially, we verified that the anti 3rd-party Tcm can also
kill murine A20 lymphoma cells in-vitro (34.8612.1% after 16hrs of
co-incubation). This killing was mediated by apoptosis (AnnexinV
staining of A20 cells increased from 5.262%, to 14.864.5%, p\
0.05). Next, using a model simulating minimal residual disease, we
followed luciferase expressing A20 cells in-vivo, and studied the ef-
fect of adding Tcm to BMT. Thus, lethally irradiated BALB/c
mice were transplanted with 3x106 allogeneic Nude B6 BM and
5000 A20 cells.While all 8 untreated mice died from tumor overload
by day 28, treatment with 5x106 donor type Tcms one day post BMT
led to tumor elimination and overall survival of 100% (7/7) 100 days
post BMT, without any manifestation of GVHD.
Collectively, our data suggest that anti 3rd-party Tcm can provide
a ‘double supportive effect’ by promoting BM engraftment under
RIC, and inducing GVL reactivity, without causing GVHD. Such
cell therapy could be highly attractive for patients with B cell malig-
nancies who might not tolerate aggressive conditioning.371
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This study compared the results of allogeneic peripheral blood
stem cell transplantation (PBSCT) from unrelated and related do-
nors in 142 consecutive patients with AML. Among these patients,
101 (71.1%) received an HLA-matched related PBSCT and 41
(28.9%) an HLA-matched unrelated PBSCT. High-risk AML was
defined as the presence of adverse cytogenetics or failure to achieve
CR. Among the 41 (28.9%) patients assigned to the high-risk group,
35 (85.4%) patients had failed to achieve CR and 7 patients (17.1%)
had adverse cytogenetics. The cumulative incidence of acute graft-
versus-host disease (GVHD)was 37.6% in the related PBSCTgroup
and 53.7% in the unrelated PBSCT group. The cumulative inci-
dence of extensive chronic GVHD was higher in the unrelated
PBSCT group (19.5%) than in the related PBSCT group (8.9%).
The overall survival (OS) rate at 4 years was 62.465.4% and
53.861.2% and the cumulative incidence of relapse was 24.8%
and 12.2% in the related and unrelated PBSCT groups, respectively.
In a multivariate analysis, unrelated PBSCT was identified as a risk
factor for the development of extensive chronicGVHD (hazard ratio
5 3.019, P-value5 0.027). Among the factors examined, unfavorable
cytogenetics and the disease status at the time of transplantationwere
found to be related with overall survival. In the case of high-risk
AML, the survival rate and relapse incidencewere significantly better
in thematched unrelated PBSCTgroup (P-value5 0.047, P-value5
0.039, respectively). In conclusion, the alloPBSCT outcomes for
AML were comparable in the matched related and matched unre-
lated groups. Nonetheless, for high-risk AML patients, matched un-
related PBSCT was found to be preferable to matched related
PBSCT.372
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Adoptive cell transfer of FoxP3+ regulatory T cells (Tregs) has
been proposed as a novel therapy for prevention of acute GVHD.
Such therapy may theoretically be limited by conversion of Tregs
into pathological effector T cells due to STAT3-activating inflam-
matory cytokines, including IL-6, IL-21, and IL-23. To better un-
derstand the role of STAT3 in Treg cell plasticity during acute
GVHD, we used a B6 0 BALB/c transplantation model. Donor
cell populations were obtained from either, STAT3 fl/fl Foxp3-
GFP (WT) or CD4-Cre, STAT3 fl/fl-Foxp3 GFP (KO). Transfer
of T cell-replete, WT inocula uniformly resulted in lethality by
day 14 post-BMT; in contrast, T cell-replete, STAT3-KO recipients
had 100% post-BMT survival (p\ 0.001). Relative to WT recipi-
ents, STAT3-KO recipients also had less GVHD by histology as-
sessment (p\ 0.05) and had increased numbers of splenic FoxP3+
T cells post-BMT (p 5 0.005); in contrast, WT recipients had in-
creased IL-17 and IFN-g secreting T cells post-BMT (each, p\
0.01). The increased number of post-BMT FoxP3+ cells in
STAT3-KO recipients may have been due to: (1) increase in ‘‘in-
duced’’ Tregs from the na€ıve T cell pool; and (2) decrease in loss
of ‘‘natural’’ (n)Tregs. Purified, na€ıve, FoxP3 negative T cells from
WT or STAT3KO donors were transferred to evaluate the first pos-
sibility: after allogeneic BMT, FoxP3 induction was greatly in-
creased in STAT3-KO recipients relative to WT recipients (p \
0.01). And, to address the second possibility, purified WT and
STAT3-KO FoxP3+ Tregs were co-infused with conventional do-
nor T cells: relative to recipients of WT nTregs, recipients of
STAT3-KO nTregs had greatly increased post-BMT numbers of
FoxP3 post-BMT (p\0.05). As such, the in vivo pool of Treg cells
after allogeneic BMT is controlled to a great extent by STAT3 sig-
naling, which influences both natural and induced Treg pathways.373
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Purpose: We retrospectively assessed changes in the incidence and
causes of non-relapse mortality (NRM) over the last 12 years in
allo-HCT patients.
Methods:We analyzed a nationwide registry database that includes
patients aged 16 years or older with AML or ALL in remission, or
low-risk MDS who received allo-HCT from 1997 to 2008. We
compared the incidence of NRM and overall survival (OS) after
allo-HCT in three consecutive four-year periods (1997-2000,
2001-2004, and 2005-2008) for younger patients (16-49 years), and
in the later two periods for older patients ($ 50 years). Subgroup
analyses were performed based on patient age and donor source:
HLA-matched/1-Ag mismatched related donor (related donor)
versus unrelated BM or CB donor (alternative donor).
Results: A total of 6517 patients with a median age of 40 years were
analyzed and the median follow-up was 39 months. A total of 1354,
2298, and 2865 allo-HCT were performed in 1997-2000, 2001-
2004, and 2005-2008, respectively. The incidence of NRM was
23% at 3 years after allo-HCT. A subgroup analysis of younger pa-
tients who received allo-HCT from a related donor showed that
there was no significant change in NRM (12-15%). In younger pa-
tients who received allo-HCT from an alternative donor, the
